
EASL Education
@EASLedu
Followers
13K
Following
11K
Media
4K
Statuses
20K
@EASLedu brings you the latest on #liver research & education. Visit #EASLCampus ----------------- EASL does not express any political opinion. RT ≠ endorsement
Joined January 2016
#LiverX, don't miss your chance to apply for the @EASLnews - @AASLDtweets Masterclass 2025 for a unique opportunity to grow as a future leader in academic hepatology.🤩. 🗓️ Deadline: 13 July 2025.📍 Éincourt-Sainte-Marguerite, France.🔗 More info below 👇. @Yujun__Wong.
Last chance to apply for the EASL-@AASLDtweets Masterclass!.This is a key opportunity to sharpen your leadership, communication & career skills! From mentorship to publishing, negotiation to networking — prepare to thrive in academic & clinical life. ❗Application deadline: this
0
3
8
RT @DebbieShawcros1: 👇👇👇👇👇👇👇👇.The @EASLedu Fellowships are back! We look forward to hearing from you 👂Please do apply.
0
2
0
RT @FrontGastro_BMJ: 🧒➡️🧑 From paediatric to adult care—are we ready?. What every adult hepatologist needs to know about transition clinics….
0
6
0
RT @rabataller: Two key points that we need to remember about the new SLD (Steatotic Liver Disease) nomenclature:. 1️⃣ SLD ≠ MASLD — it als….
0
22
0
RT @massimoiava: It's been a while since I last posted on X, but I think this is a great opportunity: the @EASLedu and @AASLDtweets Masterc….
0
3
0
RT @ef_clif: Ready to take your next career step in liver disease research? Prof. @JonelTrebicka introduces #ClinicalResearch in #Hepatolog….
0
4
0
RT @PSCSupportUK: A simple blood test for bile duct cancer could be life-changing for people with PSC. We’re funding research to develop on….
0
3
0
RT @APASLnews: Please check it out !! : Original article in Hepatology International. Read the full article: https:….
0
5
0
RT @ReibergerThomas: Drs. @LorenzBALCAR of @MedUni_Wien & @martatonon935 identify a #cirrhosis population with #ascites at particular risk….
0
19
0
📊 New #ReadOfTheWeek: SPISE and METS-IR are powerful, non-invasive predictors of pediatric #MASLD. 👉 Validated in NHANES (n=1,150) & real-world clinical cohort (n=260).👉 Outperformed TG/HDL and TyG in MASLD prediction (AUCs >0.90) across sexes.👉 Optimal cut-offs: SPISE <7.004.
In today’s #readoftheweek📚, learn how METS-IR and SPISE are effective, non-invasive markers for predicting pediatric #MASLD, which offer valuable tools for early detection and improved clinical management. Read here this @JHEP_Reports article: @yonsei_u
0
1
3
RT @ArndtVogel: Global Trend of MASH-associated Liver Cancer: A Systematic Analysis From the Global Burden of Disease 2021.@AGA_CGH .https:….
0
10
0
RT @TamCarg: It was an honour to host the @EASLedu Basic Science School at the TGLU Oxford @TGU_Oxford @NDMOxford with a brilliant keyn….
0
11
0
RT @DraMartaAlonsoP: Such a privilege to learn from all the @TGU_Oxford team!.Thank you so much for your effort and kindness @TamCarg.
0
1
0
🚨 New #ReadOfTheWeek on the prognostic value of residual ascites post-TIPS . 👉Cohort: 292 patients with cirrhosis, stratified by #ascites grade at 3 months (36% none; 28% minimal; 36% mod/sev).👉 Minimal ascites independently predicted:. 🔎further decompensation (aSHR 1.76;.
The authors in today’s #readoftheweek📚 evaluated the prognostic relevance of residual ascites grades in patients with advanced chronic liver disease after #TIPS placement. Read here this @JHEP_Reports article: 🙏 @hartl_md, @mathiasjachs, @tiede_anja,
0
10
16